| Clinical Publications |
Scientific Publications |
| June 2022 |
Future management of chronic myeloid leukemia: From dose optimization to new agents
Breccia M et al. Curr Cancer Drug Targets
(epub ahead of print)
|
Modified dentritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Du Z et al. Exp Hematol Oncol, June 2022
– open access publication |
The outcomes of ponatinib therapy in patients with CML resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the Donation Program
Sacha T et al. Clin Lymphoma Myeloma, June 2022
– open access publication |
Atypical activation of signaling downstream of inactivated BCR-ABL mediates chemoresistance in chronic myeloid leukemia
Narasimhan M et al. J Cell Commun Signal, June 2022 (epub ahead of print) – open access publication
|
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia:
a post-marketing surveillance study in Korea
Ahn SY et al. Blood Res, June 2022
(epub ahead of print)
– open access publication
|
Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia
Ozel B et al. Med Oncol, June 2022 |
Out comes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
Sanz A et al. Blood Cancer J, June 2022
– open access publication
|
BCR-ABL1∆E7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Tan Y et al. Hematol Oncol, June 2022
(epub ahead of print) |
Bosutinib-induced lung injury: a report of two cases and literature review
Watanabe N et al. Int J Hematol, June 2022
– open access publication |
The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug
Teng M et al. J Med Chem, June 2022
(epub ahead of print) |
| |
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
Liu C et al. Cell Metabol, June 2022 |
| |
CRISPR/Cas9-directied gene trap constitutes a selection system for corrected BCR/ABL leukemic cells in CML
Vuelta E et al. Int J Mol Sci, June 2022
– open access publicatio
|
| May 2022 |
How I treat chronic-phase chronic myelogenous leukemia
Berman E. Blood, May 2022 |
Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors
de Almeida FC et al. Front Immunol, April 2022
– open access publication |
Asciminib: new therapeutic option in chronic-phase CML with treatment-failure
Yeung DT et al. Blood, April 2022 (epub ahead of print) |
RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia
Shanmunagathan N et al. J Mol Diagn, May 2022
(epub ahead of print) |
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
Lu L et al. Br J Haematol, May 2022
(epub ahead of print) – open access publication |
Novel tyrosine kinase inhibitors to target chronic myeloid leukemia
Ciaffaglione V et al. Molecules, May 2022
– open access publication |
Chronic myeloid leukemia: a type of MPN
Samad MA et al. Blood Res, May 2022
(epub ahead of print)
– open access publication |
Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects
Senapati J and Sasaki K. Cancers(Basel), May 2022
– open access publication
|
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia – What to look for when treatment-free remission is not an option
Lipton JH et al. Blood Rev, May 2022
(epub ahead of print) – open access publication |
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients
Shehata AMF et al. Leuk Res, May 2022
|
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Brümmendorf TH et al. Leukemia, May 2022
(epub ahead of print) – open access publication |
Peripheral blood CD26 positive leukemia stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia
Ebjan HF et al. Leuk Res Rep, May 2022
– open access publication
|
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Flynn KE et al. Haematologica, May 2022
(epub ahead of print) – open access publication |
|
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
White HE et al. Leukemia, May 2022
(epub ahead of print) – open access publication |
|
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
Yang J et al. Expert Rev Hematol, May 2022
(epub ahead of print) |
|
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM-2 trial
Dulucq S et al. Haematologica, May 2022
(epub ahead of print) – open access publication |
|
Lower tumour burden is associated with better cognitive function in patients with chronic-phase chronic myeloid leukemia
Li Z et al. Leuk Lymphoma, May 2022
(epub ahead of print) |
|
Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience
Szczepanek E et al. Leuk Lymphoma, May 2022
(epub ahead of print) |
|
| April 2022 |
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
Gugliotta G et al. Haematologica, April 2022
(epub ahead of print) – open access publication |
Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide
Zheng X et al. Oncol Lett, April 2022
– open access publication |
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success
Inzol E et al. Am J Hematol, April 2022
(epub ahead of print) – open access publication |
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Adnan Awad S et al. Blood Cancer J, April 2022
– open access publication |
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
Haddad F et al. Leuk Lymphoma, April 2022
(epub ahead of print) |
Aberrant hyrdroxymethylation in promoter CpG regions of genes related to the cell cycle apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival
Guru SA et al. BMC Cancer, April 2022
– open access publication |
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation
Shimazu Y et al. Hematol Oncol, April 2022
(epub ahead of print) |
Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy
Li Y et al. Cell Death Discov, April 2022
– open access publication |
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukemia
Shivarov V and Grigorova D. Br J Haematol, April 2022 (epub ahead of print) – open access publication |
|
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic leukemia in the United Kingdom and The Netherlands
Claudiani S et al. Eur J Haematol, April 2022
(epub ahead of print) |
|
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?
Bhreathnach Ú and Langabeer SE. Int J Lab, April 2022 (epub ahead of print) – open access publication
|
|
Aleukemic extramedullary blast crisis as an initial presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion transcript
Miyashita N et al. Int Med, April 2022 (epub ahead of print)
– open access publication
|
|
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
García-Gutiérrez V and Hernandez-Boluda JC. Expert Rev Hematol, May 2022 (epub ahead of print) |
|
| March 2022 |
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
Takahashi N et al. Int J Hematol, March 2022
(epub ahead of print) – open access publication |
Another Philadelphia story
Radich J. Haematologica, March 2022
– open access publication |
Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in hematology
Saglio G et al. Bone Marrow Transplant, March 2022 (epub ahead of print) – open access publication |
The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients
Park H et al. Leuk Res, March 2022 |
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in real-life: A Campus CML study
Iurlo A et al. Front Oncol, March 2022
– open access publication |
The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
Kumar R et al. Blood Adv, March 2022
(epub ahead of print) – open access publication |
Prevalence of anemia among chronic myeloid leukemia patients treated with imatinib: A evidence based meta-analysis
Singh AK et al. Curr Rev Clin Exp Pharmacol, March 2022 (epub ahead of print) |
Targeting BCR-ABL in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski R. Pharmacol Res, March 2022
(epub ahead of print) |
Molecular monitoring of BCR-ABL fusion transcripts in patients with chronic myeloid leukemia during treatment using the endpoint fluorescence method
Amin H and Ahmed S. Lab Med, March 2022 |
A kinase inhibitor which specifically targets the ABL myristate pocket (STAM), but unlike asciminib crosses the blood-brain barrier
Manley PW et al. Bioorg Med Chem Lett, March 2022 |
The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation
Tachibana T et al. Transplant Cell Ther, March 2022 (epub ahead of print) |
FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via non-canonical κB-kappa B signaling activation
Yang T et al. J Exp Clin Cancer Res, March 2022
– open access publication |
Outcomes of pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review
Castillo DL et al. Hematol Rep, March 2022
– open access publication |
Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapyExpression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapy
Toloza MJ et al. Gene, March 2022 |
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentrations in patients with chronic myeloid leukemia receiving first-line nilotinib therapy
Fukuda N et al. Cancer Chemother and Pharmacol, March 2022 (epub ahead of print)
– open access publication |
MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukemia cells to imatinib by inhibiting mTor signalling
Liu X et al. Acta Hematol, March 2022
(epub ahead of print) |
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukemia
Baccarani M et al. Leukemia, March 2022
(epub ahead of print) – open access publication |
|
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukemia model
Lindström HJG and Friedmann R. Sci Rep,
March 2022 – open access publication |
|
| February 2022 |
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation
Shatty D et al. Asia Pac J Clin Oncol, February 2022
– open access publication |
TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells
Sun H et al. Int J Oncol, March 2022
(epub ahead of print)
– open access publication
|
Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A Pairwise and Bayesian Network Meta-Analysis
Chen K et al. Front Oncol, February 2022
– open access publication |
A systematic review of candidate miRNAs, its targeted genes and pathways in CML – An integrated bioinformatical analysis
Elias MH et al. Front Oncol, March 2022
– open access publication |
Extramedullary early T-cell lymphoblastic crisis in a young pregnant chronic myeloid leukemia patient: Diagnosis with fine needle aspiration cytology and flow cytometry
Murugan R et al. Diagn Cytopathol, Feb 2022 (epub ahead of print) |
Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia cells
Ianniciello A and Helgasson GV. Autophagy, March 2022
(epub ahead of print) |
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive phase in Taiwan
Hwang WL et al. Int J Hematol, February 2022 (epub ahead of print) |
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, March 2022
– open access publication |
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
Shelton DN et al. PLoS One, March 2022
– open access publication |
Commentary on Dominy et al.: Assessment of qualitative PCR for BCR-ABL1 transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Branford S. Br J Haematol, February 2022
(epub ahead of print)
– open access publication |
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Robin JB et al. Ann Hematol, March 2022
(epub ahead of print) |
Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print) |
Management of chronic myeloid leukemia and pregnancy:
A Bibliometric Analysis (2000-2020)
Wang Y et al. Front Oncol, March 2022
– open access publication |
Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication |
Transcript and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Kumar V et al. Mol Cell Biochem, February 2022 (epub ahead of print) |
Genomic mechanisms influencing outcome in chronic myeloid leukemia
Fernandes A et al. Cancers(Basel), January 2022 – open access publication |
Olverembatinib: First Approval
Dhillon S et al. Drugs, February 2022
(epub ahead of print) |
Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission
Stuckey R et al. Curr Oncol Rep, February 2022
(epub ahead of print) |
A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy
Zhang XS et al. Leukemia, February 2022
(epub ahead of print) |
Validation and refinement of RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, February 2022
(epub ahead of print)
– open access publication |
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
Pokorny R et al. J Oncol Pharm Pract, February 2022
(epub ahead of print)
– open access publication |
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia
Kamachi K et al. Cancer Lett, February 2022 – open access publication |
| |
Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022 |
| |
Waking up CML leukemia stem cells for the kill
Lv K and Tong W. Blood, February 2022
– open access publication |
| |
Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print) |
| |
Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication |
|
|
Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022 |
| January 2022 |
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukemia
Gallipoli P et al. Br J Haematol, January 2022
(epub ahead of print)
– open access publication |
The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemia cell differentiation
Shahzad Ali M et al. J Clin Med, January 2022
– open access publication |
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
Januzzi JL et al. J Hematol Oncol, January 2022
– open access publication |
BCR-ABL1 tyrosine kinase complex signalling transduction:
challenges to overcome resistance in chronic myeloid leukemia
Amarante-Mendes GP et al. Pharmaceutics, January 2022
– open access publication |
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors:
Follow-up of patients diagnosed 2002 – 2017 in a complete coverage and nationwide agnostic register study
Dahlén T et al. Am J Hematol, January 2022
(epub ahead of print)
– open access publication |
Imatinib can act as an allosteric activator of ABL kinase
Xie T et al. J Mol Biol, January 2022 |
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
Réa D and Hughes TP. Crit Rev Oncol Hematol,
January 2022
(epub ahead of print)
– open access publication |
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Tanaka Y et al. Nat Commun, January 2022
– open access publication |
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM et al. Br J Haematol, January 2022
(epub ahead of print) |
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
Louati N et al. J Oncol Pharma Pract, January 2022 |
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: Who can benefit the most?
Efficace F and Baccarani M. J Natl. Cancer Inst,
January 2022
– open access publication |
Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases
Schwarz A et al. Cancers(Basel), January 2022
– open access publication |
The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review
Arzoun H et al. Cureus, January 2022
– open access publication |
P-Loop mutations-negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients
Kaleem B et al. Int J Lab Hematol, January 2022
(epub ahead of print)
|
Asciminib: First Approval
Deeks ED et al. Drugs, January 2022
(epub ahead of print) |
The prognosis biomarkers based on m6A-related IncRNAs for myeloid leukemia patients
Yang LR et al. Cancer Cell Int, January 2022
– open access publication |
Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors
Shaya J et al. Clin Lymphoma Myeloma Leuk, January 2022
– open access publication |
Pterostilbene downregulated BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
Kawakami S et al. Sci Rep, January 2022
– open access publication |
|
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Kee KM et al. Leuk Res, January 2022
|
Novel mechanism by a Bis-Pyridinium fullerene derivate to induce apoptosis by enhancing the MEK-ERK pathway in a reactive oxygen species-independent manner in BCR-ABL-positive chronic myeloid leukemia-derived K562 cells
Sumi K et al. Int J Mol, January 2022
– open access publication |
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
